NCT02062385View on ClinicalTrials.gov

Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

PHASE3CompletedINTERVENTIONAL
Enrollment

4,040

Participants

Timeline

Start Date

May 30, 2014

Primary Completion Date

June 11, 2015

Study Completion Date

June 11, 2015

Conditions
Rotavirus Gastroenteritis
Interventions
BIOLOGICAL

V260

V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)

BIOLOGICAL

Placebo to V260

Placebo control

BIOLOGICAL

OPV

Oral poliovirus vaccine administered according to the standard of care

BIOLOGICAL

DTaP

Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02062385 - Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024) | Biotech Hunter | Biotech Hunter